➀ Researchers at the University of Pennsylvania and Moderna have developed a lipid nanoparticle-encapsulated mRNA therapy that significantly improves survival and reduces leucine levels in a mouse model of maple syrup urine disease (MSUD). ➁ The treatment strategy considers all genetic mutations causing MSUD and shows potential as a long-term universal treatment approach. ➂ Additionally, the Wilson lab has discovered novel AAV variants with improved biodistribution properties, potentially enhancing gene therapy targeting tissues other than the liver.
Related Articles
- Promising New Platform for Brain-Targeted mRNA Delivery8 months ago
- uniQure N.V.: A Potential Huntington's Play8 months ago
- Improving Gene Therapy Accuracy with Nanosensorsabout 1 year ago
- Lipid Nanoparticles Deliver Nucleic Acid to Stimulate Anti-Tumor Immunityabout 1 year ago